UrviAjayShahMD

Hematologic Oncology

Physician

Overview of Dr. Shah

Dr. Urvi Shah is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Montefiore Medical Center. She received her medical degree from Grant Medical College and has been in practice 6 years. She is one of 113 doctors at Montefiore Medical Center and one of 494 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She has more than 80 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(571) 252-5248

Education & Training

Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2015 - 2018
Tufts Medical CenterResidency, Internal Medicine, 2012 - 2015
Grant Medical CollegeClass of 2011

Certifications & Licensure

NY State Medical License 2018 - 2026
NJ State Medical License 2022 - 2025
MA State Medical License 2012 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) Start of enrollment: 2021 Jun 03
Active, not recruiting
Not Applicable
Roles: Contact, Principal Investigator
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma Start of enrollment: 2019 Nov 19
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) Start of enrollment: 2019 Sep 23
Active, not recruiting
Phase 1
Roles: Contact
A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide Start of enrollment: 2020 Aug 28
Recruiting
Phase 2
Roles: Contact, Principal Investigator
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) Start of enrollment: 2023 Sep 20
Recruiting
Not Applicable
Roles: Principal Investigator, Contact
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) Start of enrollment: 2022 Nov 29
Recruiting
Not Applicable
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

38 citations
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
Oliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine, Tasmin Farzana, Adolfo Aleman
Blood. 2023-02-16
107 citations
GPRC5D-Targeted CAR T Cells for Myeloma.
Sham Mailankody, Sean M Devlin, Jonathan Landa, Karthik Nath, Claudia Diamonte
The New England Journal of Medicine. 2022-09-29
58 citations
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: Th...
Ola Landgren, Malin Hultcrantz, Benjamin Diamond, Alexander M. Lesokhin, Sham Mailankody
JAMA Oncology. 2021-06-01

Journal Articles

Cancer and Coronavirus Disease 2019 (COVID-19)—Facing the “C Words”
Urvi Shah, MD, JAMA Oncology

Abstracts/Posters

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
Urvi A Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
Urvi A Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Effect of Active Hepatitis C Infection in Relapse-Free Survival Among Patients with HIV_Related Diffuse Large B_Cell Lymphoma
Urvi A Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis
Urvi A Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Conventional Chemotherapy Treatment Induces Unique Patterns of Clonal Evolution in a North American Adult T Cell Leukemia/Lymphoma Cohort
Urvi A Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy
Urvi A Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
Urvi A Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

The Rising Number of Adult T Cell Leukemia Lymphoma (ATLL) Cases in Non-Hispanic Blacks and Its Association with Poor Outcomes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Differentiating Lung Involvement in Adult T-Cell Leukemia Lymphoma (ATLL) Versus HTLV Infection: Results from a Large Single-Center Cohort with Implications for Stagin...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Cancer and Coronavirus Disease 2019 (COVID-19)—Facing the “C Words”May 2020
Cancer and Coronavirus Disease 2019 (COVID-19)—Facing the “C Words”May 2020
Cancer and Coronavirus Disease 2019 (COVID-19)—Facing the “C Words”May 2020

Press Mentions

International Myeloma Foundation Medical Student Scholars for Health Equity in Myeloma Present Posters at the 2024 NMA Annual Convention & Scientific AssemblyAugust 15th, 2024
Cholesterol, Triglycerides, and Nutrition: How Your Diet May Increase Your Cancer OddsJuly 1st, 2024
Plantable Health Announces Preliminary Results from Its Myeloma Cancer TrialOctober 4th, 2022
Join now to see all